DF 1283

Drug Profile

DF 1283

Latest Information Update: 09 May 1996

Price : $50

At a glance

  • Originator Dompe
  • Class Antibronchitics
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Bronchitis; Cystic fibrosis; Emphysema

Most Recent Events

  • 09 May 1996 Discontinued-Preclinical for Adult respiratory distress syndrome in Italy (PO)
  • 09 May 1996 Discontinued-Preclinical for Emphysema in USA (PO)
  • 09 May 1996 Discontinued-Preclinical for Cystic fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top